Therapy Areas: Oncology
Natera Signatera gains PMDA approval in Japan for colorectal cancer testing
24 June 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) announced on Wednesday that its Signatera test has received regulatory approval from Japan's Pharmaceuticals a...
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead...
Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes
23 June 2026 - Clinical-stage oncology company Oxford BioTherapeutics (OBT) on Monday announced two new clinical milestones with Boehringer Ingelheim-partnered programmes, BI 3820768 (OB33) and obrixt...
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer
22 June 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering the u...
Transgene expands myvac platform into non-small cell lung cancer with TG4070
22 June 2026 - French biotech company Transgene (Euronext Paris:TNG) announced on Monday that it has initiated a randomised Phase 1 trial of TG4070, an individualised neoantigen therapeutic vaccine, i...
Arletta Pharma Solutions names new chief medical officer
22 June 2026 - Arletta Pharma Solutions, a Netherlands-based biopharmaceutical company specialising in innovative therapies for women diagnosed with Female Sexual Disorders (FSD), announced on Friday ...